B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aytu Biopharma Inc (NQ: AYTU )

2.804 -0.107 (-3.66%)
Streaming Delayed Price Updated: 9:42 AM EDT, Jul 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 670
Open 2.870
Bid (Size) 2.800 (2)
Ask (Size) 2.930 (5)
Prev. Close 2.910
Today's Range 2.804 - 2.870
52wk Range 1.520 - 3.500
Shares Outstanding 5,567,490
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms
Via ACCESSWIRE
Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and... 
Via Newsfile

Performance

YTD
-2.99%
-2.99%
1 Month
-9.27%
-9.27%
3 Month
-15.05%
-15.05%
6 Month
+3.07%
+3.07%
1 Year
+58.39%
+58.39%

More News

Read More
Aytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
Via ACCESSWIRE
AYTU Stock Earnings: Aytu BioPharma Beats EPS, Beats Revenue for Q3 2024
Via InvestorPlace
Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024
Via ACCESSWIRE
Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024
Via ACCESSWIRE
Earnings Scheduled For February 14, 2024
Via Benzinga
Earnings Preview: Aytu BioPharma
Via Benzinga
Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023
Via ACCESSWIRE
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter
Via ACCESSWIRE
Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024
Via ACCESSWIRE
Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
Via ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results
Via ACCESSWIRE
Aytu BioPharma's Earnings: A Preview
Via Benzinga
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year
Via ACCESSWIRE
Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023
Via ACCESSWIRE
Biggest Short Squeeze Stocks Of The Week: Biotech Stocks Dominate, A Bitcoin-Related Stock Moves Up Leaderboard
Via Benzinga
Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement
Via ACCESSWIRE
Aytu BioPharma Inc. (NASDAQ: AYTU) Near the Top of Equities by Percentage Gain on 9/28
Via Investor Brand Network
Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why CarMax Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.